{
    "2019-10-12": [
        [
            {
                "time": "2023-10-12",
                "original_text": "Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Positive Phase 3 Data",
                        "Abrocitinib",
                        "Moderate to Severe Atopic Dermatitis",
                        "European Academy of Dermatology and Venereology"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "n/a"
                }
            }
        ]
    ]
}